title: [Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases].
abstract: OBJECTIVE
  Cetuximab combined with radiotherapy or chemotherapy has been used to treat head and neck cancer in recent years, but few reports are available in China now. This study was to summarize our experiences in treating patients with head and neck cancer cetuximab.
  
  
  METHODS
  From October 1st, 2005 to September 30th, 2008, six with patients head and neck cancer were treated using cetuximab combined with radiotherapy and five were treated using cetuximab combined with chemotherapy in Sun Yat-sen University Cancer Center. The short-term efficacy and safety were analyzed.
  
  
  RESULTS
  A total of 82 cycles of cetuximab treatment, with a median of seven cycles, were administered safely. There was no treatment-associated death and no cetuximab-associated discontinuation. In cetuximab combined with radiotherapy group, four patients achieved complete response (CR) and two achieved partial response (PR); all CR patients had hadacne-like rash (three cases were > or = grade III), only one PR patient had grade I rash; five patients had skin reaction in the irradiation field (four cases of skin reaction were > or = grade III); hematological toxicity was slight excepted one case of grade IV. In cetuximab combined chemotherapy group, two patients achieved PR, two had stable disease (SD) and one had progressed disease (PD); the of acne-like rash was low, and three patients experienced bone marrow depression above grade III.
  
  
  CONCLUSIONS
  Cetuximab combined with either radiotherapy or chemotherapy are good options for suitable patients with head and neck cancer.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China. xialiangping@163.com
authors.forename: Liang-Ping
authors.initials: LP
authors.lastname: Xia
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.forename: Mao-Zhen
authors.initials: MZ
authors.lastname: Liu
authors.forename: Pi-Li
authors.initials: PL
authors.lastname: Hu
authors.forename: Xu-Xian
authors.initials: XX
authors.lastname: Chen
authors.forename: Gui-Fang
authors.initials: GF
authors.lastname: Guo
authors.forename: Hui-Juan
authors.initials: HJ
authors.lastname: Qiu
authors.forename: Yu-Ming
authors.initials: YM
authors.lastname: Rong
authors.forename: Sui-Yi
authors.initials: SY
authors.lastname: Qian
authors.forename: Fei-Fei
authors.initials: FF
authors.lastname: Zhou
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Huang
authors.forename: Tao-Li
authors.initials: TL
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D000068818:Cetuximab; D003131:Combined Modality Therapy; D018450:Disease Progression; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab